{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:19:00Z","timestamp":1787761140332,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"\n Background:<\/jats:title>\n Hydrocortisone showed an important role in reversal of shock when added to standard therapy in managing septic shock. Hyperglycemia is one of the most common side effects associated with corticosteroid treatment.<\/jats:p>\n <\/jats:sec>\n \n Aims:<\/jats:title>\n This study aimed to evaluate the risk of hyperglycemia of intermittent hydrocortisone boluses versus continuous infusion in septic shock patients.<\/jats:p>\n <\/jats:sec>\n \n Settings and Design:<\/jats:title>\n This was a prospective randomized controlled study conducted in a tertiary care teaching hospital.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n \n One hundred and forty patients with septic shock and who received noradrenaline were enrolled in this randomized study. Group 1 was intermittent bolus hydrocortisone group (\n n<\/jats:italic>\n = 70) and Group 2 was continuous infusion group (\n n<\/jats:italic>\n = 70). All patients who were admitted with septic shock and who received noradrenaline and hydrocortisone were included in the study. Those patients who had exceeded 200 mg per day of hydrocortisone were excluded from the study. The primary outcome of the study was mean blood glucose.\n <\/jats:p>\n <\/jats:sec>\n \n Statistical Analysis Used:<\/jats:title>\n \n Qualitative variables were compared between the two groups with the Chi-square of the Fisher's exact test and continuous variables were compared using the Student's\n t<\/jats:italic>\n -test or the Wilcoxon rank-sum test.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Out of 112 patients, 54 patients received hydrocortisone as intermittent boluses (48.2%), and 58 patients (51.8%) received continuous infusion. For the primary outcome, no statistically or clinically significant difference was found in the blood glucose estimated marginal mean: 154.44 mg.dL\n \u22121<\/jats:sup>\n (95% confidence interval [CI]: 144.18\u2013166.88) in the bolus group and 160.2 mg.dL\n \u22121<\/jats:sup>\n (95% CI: 143.82\u2013176.76) in the infusion group with a mean difference of 05.76 mg.dL\n \u22121<\/jats:sup>\n (95% CI: \u221213.86\u201325.38). For the secondary outcomes of the study, no difference was found between the two groups in hyperglycemic or hypoglycemic events, mortality, length of stay in intensive care unit, and reversal of shock.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n The risk of hyperglycemia is almost equal in both intermittent and continuous infusions of hydrocortisone in septic shock patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/aer.aer_115_22","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T10:21:30Z","timestamp":1670581290000},"page":"321-325","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses versus Continuous Infusion in Septic Shock"],"prefix":"10.4103","volume":"16","author":[{"given":"Ganesh Kumar","family":"Ram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurav","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Bahadur","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeet Rana","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20240901","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":"Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care","volume":"29","author":"Angus","year":"2001","journal-title":"Crit Care Med"},{"key":"R2-7-20240901","doi-asserted-by":"crossref","first-page":"e107181","DOI":"10.1371\/journal.pone.0107181","article-title":"Epidemiology and outcome of severe sepsis and septic shock in Intensive Care Units in Mainland China","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"},{"key":"R3-7-20240901","doi-asserted-by":"crossref","first-page":"e002586","DOI":"10.1136\/bmjopen-2013-002586","article-title":"Sepsis-associated mortality in England: An analysis of multiple cause of death data from 2001 to 2010","volume":"3","author":"McPherson","year":"2013","journal-title":"BMJ Open"},{"key":"R4-7-20240901","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"R5-7-20240901","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2174\/138161208784980626","article-title":"Adrenal insufficiency in sepsis","volume":"14","author":"Annane","year":"2008","journal-title":"Curr Pharm Des"},{"key":"R6-7-20240901","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s00134-004-2210-z","article-title":"Surviving sepsis campaign guidelines for management of severe sepsis and septic shock","volume":"30","author":"Dellinger","year":"2004","journal-title":"Intensive Care Med"},{"key":"R7-7-20240901","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2110-5820-1-7","article-title":"Corticosteroids for severe sepsis: An evidence-based guide for physicians","volume":"1","author":"Annane","year":"2011","journal-title":"Ann Intensive Care"},{"key":"R8-7-20240901","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13054-017-1659-4","article-title":"Corticosteroids in septic shock: A systematic review and network meta-analysis","volume":"21","author":"Gibbison","year":"2017","journal-title":"Crit Care"},{"key":"R9-7-20240901","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1705835","article-title":"Adjunctive glucocorticoid therapy in patients with septic shock","volume":"378","author":"Venkatesh","year":"2018","journal-title":"N Engl J Med"},{"key":"R10-7-20240901","doi-asserted-by":"crossref","first-page":"S527","DOI":"10.1097\/01.CCM.0000142983.15421.11","article-title":"Use of corticosteroid therapy in patients with sepsis and septic shock: An evidence-based review","volume":"32","author":"Keh","year":"2004","journal-title":"Crit Care Med"},{"key":"R11-7-20240901","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa071366","article-title":"Hydrocortisone therapy for patients with septic shock","volume":"358","author":"Sprung","year":"2008","journal-title":"N Engl J Med"},{"key":"R12-7-20240901","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.4065\/78.12.1471","article-title":"Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients","volume":"78","author":"Krinsley","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"R13-7-20240901","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1097\/CCM.0b013e3181b083f7","article-title":"Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis","volume":"37","author":"Falciglia","year":"2009","journal-title":"Crit Care Med"},{"key":"R14-7-20240901","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00134-007-0540-3","article-title":"Impact of bolus application of low-dose hydrocortisone on glycemic control in septic shock patients","volume":"33","author":"Weber-Carstens","year":"2007","journal-title":"Intensive Care Med"},{"key":"R15-7-20240901","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1186\/cc5696","article-title":"Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: A prospective randomized trial","volume":"11","author":"Loisa","year":"2007","journal-title":"Crit Care"},{"key":"R16-7-20240901","first-page":"252","article-title":"Evaluation of hydrocortisone continuous infusion versus intermittent boluses in resolution of septic shock","volume":"42","author":"Hoang","year":"2017","journal-title":"P T"},{"key":"R17-7-20240901","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SHK.0000000000001316","article-title":"Comparison between continuous and intermittent administration of hydrocortisone during septic shock: A randomized controlled clinical trial","volume":"52","author":"Tilouche","year":"2019","journal-title":"Shock"},{"key":"R18-7-20240901","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5005\/jp-journals-10071-23501","article-title":"Hyperglycemia risk evaluation of hydrocortisone intermittent boluses versus continuous infusion in septic shock: A retrospective study","volume":"25","author":"Mitwally","year":"2021","journal-title":"Indian J Crit Care Med"}],"container-title":["Anesthesia Essays & Researches"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aer.aer_115_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:24:36Z","timestamp":1787757876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aer.aer_115_22"}},"subtitle":["A Prospective Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/aer.aer_115_22","relation":{},"ISSN":["0259-1162"],"issn-type":[{"value":"0259-1162","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}